Applications published 4 July 2007

Inhibition of tumour cell migration
GW Pharma 1802274*

Taste-masking pharmaceutical compsns
Sandoz 1802275*

Compsns and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
Pfizer Products 1802276*

Liposomal compsn comprising an active ingredient for relaxing smooth muscle production and therapeutic use of said compsn
Polymun Scientific Immunbiologische Forschung 1802277*

Dermal delivery of N-methyl-glucamine and N-methyl-glucamine compounds
Dynamis Therapeutics 1802278*

Carotenoid compsn and method for preparation thereof
Bos, Michael Ary; Ellis, Davis Graham 1802279*

Clopidogrel compsns
Dr Reddy's Laboratories Ltd; Dr Reddy's Laboratories 1802280*

Tablets comprising a poorly compressible active agent and tocopherol polyethyleneglycol succinate (TPGS)
Eastman Chemical Company 1802282*

Biocompatible protein particles, particle devices and methods thereof
Gel-Del Technologies 1802282*

Bilayer tablet
Boehringer Ingelheim International 1802283*

Taste-masked pharmaceutical compsns with gastrosoluble pore-formers
Eurand Pharmaceuticals 1802285*

Sustained drug release compsn demonstrating an ascending zero order release pattern, methods of manufacturing such a compsn
Alza Corp 1802286*

Minicapsule formulations
Sigmoid Biotechnologies 1802287*

Biodegradable polymeric microparticles
Alain Dreyer Brevets et Developpement 1802288*

Compsns and their uses for lysosomal enzyme deficiencies
University of Massachusetts 1802289*

Solubilising agents for active or functional organic compounds
ISP Investments 1802290*

Calixarene-based peptide conformation mimetics, methods of use, and methods of making
Regents of the University of Minnesota 1802291*

Compsns and methods for inducing hair growth
BioMAS 1802292*

Orally effective cannabinoid analogues
Pharmos Corp 1802293*

Carbamate compounds for use in treating neurodegenerative disorders
Janssen Pharmaceutica 1802294*

Oral pharmaceutical compsn for targeted transport of a platinum complex into the colorectal region, method for producing and use as a medicament thereof
Pliva-Lachema 1802295*

Acidic and buffered skin-care compsns comprising nicotin amid an absorbing agent
Bayer ConsumerCare 1802296*

Compsns and methods for treatment of disease caused by yersinia SPP infection
The Burnham Institute 1802297*

Novel agents for preventing and treating disorders connected to impaired neurotransmission
DSM IP Assets 1802298*

Ophthalmic compsns for treating ocular hypertension
Merck & Co 1802299*

Ophthalmic compsns for treating ocular hypertension
Merck & Co 1802300*

Treatment of bipolar disorders and associated symptoms
Pfizer 1802301*

Novel use of a-sympathomimetics having a 2-imidazoline structure
Merck Patent 1802302*

Compounds, compsns and methods of inhibiting a-synuclein toxicity
Whitehead Institute for Biomedical Research; Foldrx Pharmaceuticals 1802303*

Cilostazol-containing pharmaceutical compsn based on particles of less than 50 micrometres
Ranbaxy Laboratories 1802304*

Compsns and methods for disruption of BRCA2-RAD51 interaction
The Regents of the University of California 1802305*

Quinoline analogue as cell proliferation inhibitors
Cylene Pharmaceuticals 1802306*

Pyrrolidine derivatives as histamine receptors ligands
Glaxo Group 1802307*

Combination of organic compounds
Novartis 1802308*

Method and compsn for supplementation of nutritional deficiencies in renal patients
Everett Laboratories 1802309*

Use of purine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells
Centre National de la Recherche Scientifique; Universite de Poitiers 1802310*

4-aminophenyl morpholindone derivatives for the treatment of hepatitis C
Saltigo 1802311*

Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 CGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
Endorecherche 1802312*

Therapeutic agents targeting the NCCA0ATP channel and methods of use thereof
University of Maryland, Baltimore; Department of Veterans Affairs 1802313*

Compsns containing uridine, and methods utilising same
The Massachusetts Institute of Technology 1802314*

Combination therapy for treating viral infections
Achillion Pharmaceuticals 1802315*

Purine derivatives and methods of use thereof
Inotek Pharmaceuticals Corp 1802316*

Use of A2A adenosine receptor agonists
CV Therapeutics 1802317*

Lactic acid bacteria strains useful against gastrointestinal pathogens and compsns containing same
Medinova 1802318*

Lactic acid bacteria strains useful against urogenital pathogens and compsns containing the same
Medinova 1802319*

Pharmaceutical canscora diffusa-containing compsn
Barthel, Michael 1802320*

Compsns and methods for codulating PGC-1-alpha to treat neurological diseases and disorders
Dana-Farber Cancer Institute 1802321*

Prion protein binding materials and methods of use
Pathogen Removal and Diagnostic Technologies; North Carolina State University 1802322*

Plant PR-5 proteins as mammalian therapeutic agents
Purdue Research Foundation 1802323*

Intestinal epithelial glucose sensor
VIB 1802324*

Crig polypeptide for prevention and treatment of complement-associated disorders
Genentech 1802325*

Method for treating bone tumours using bone morphogenic proteins
Stryker 1802326*

Combination anti-viral compsns comprising castanospermine and methods of use
Migenix 1802327*

Use of organic compounds
Novartis 1802328*

A pharmaceutical formulation comprising crystalline insulin and dissolved insulin
Novo Nordisk 1802329*

Validation of TSSK family members and TSSK as male contraceptive targets
University of Virgina Patent Foundation 1802330*

Treatment of glomerular basement membrane diseases involving matrix matelloproteinase-12
Boys Town National Research Hospital 1802331*

Modified HIV-1 envelope proteins
The Henry M Jackson Foundation 1802332*

Antibody buffering of a ligand in vivo
Arrowsmith Technologies 1802333*

Method for treating intraocular neovascular diseases
Genentech 1802334*

Immunogenic compsns of staphylococcus epidermidis polypeptide and polynucleotide antigens
Wyeth 1802335*

Malaria prime/boost vaccines
Crucell Holland; GlaxoSmithKline; The Government of the United States, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research 1802336*

Consortium of nitrifying bacteria
Novozymes Biologicals 1802337*

High cell density process for growth of listeria
Medimmune 1802338*

Treating neoplasms with neurotoxin
Toxcure 1802339*

Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
Vakzine Projekt Management 1802340*

Combination treatment for non-haematologic malignancies using an anti-IGF-1R antibody
Pfizer Products 1802341*

Immunoadsorber for treating inflammations
Adexter Technology 1802342*

E2-EPF5, a novel therapeutic protein and target
Novartis; Novartis-Pharma 1802343*

Antibody formulation in histidine-acetate buffer
Genentech 1802344*

Methods of treating CD30 positive lymphomas
Medarex 1802345*

Sustained release pharmaceutical compsn
Smart Drug Systems 1802346*

Anti-snoring compsn
Persee Medica 1802347*

Complex containing mequitazine, a cyclodextrin and an interaction agent
Pierre Fabre Medicament 1802348*

Pharmaceutical compsns comprising a toxin-binding oligosaccharide and a polymeric particle
Ilypsa; Mong, Tony Kowk-Kong 1802349*

Modulation of neurologia-derived BDNF in the treatment and prevention of pain
Universite Laval; The Hospital for Sick Children 1802350*

Disimmortalizable mammalian chromatin cell lines for cell therapy for pain
US Department of Veterans Affairs 1802351*

Use of VCAM-1 ligands for detecting and/or treating cardiovascular diseases
Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Joseph Fourier 1802352*

Vapourised hydrogen peroxide concentration detector
Steris 1802353*